Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Michał Wiciński, Karol Górski, Eryk Wódkiewicz, Maciej Walczak, Magdalena Nowaczewska, Bartosz Malinowski
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2020-03-01
Colecção:International Journal of Molecular Sciences
Assuntos:
vildagliptin
endothelium
inflammation
atherogenesis
pathways
pharmacology
Acesso em linha:https://www.mdpi.com/1422-0067/21/7/2275
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados